PREDICTORS OF ACUTE KIDNEY DAMAGE IN PATIENTS HOSPITALIZED WITH ACUTE DECOMPENSATED HEART FAILURE
https://doi.org/10.52485/19986173_2022_3_36
Abstract
Aims. To study renal function in patients hospitalized with acute decompensated heart failure (ADHF) and factors associated with the development of acute kidney injury (AKI) during hospitalization.
Materials and methods. The study included 100 patients hospitalized with ADHF, who were divided into 2 groups depending on the development of AKI. Group 1 consisted of 79 people who did not develop AKI and group 2 consisted of 21 people who developed AKI. The criterion for the diagnosis of AKI was an increase in creatinine by 25% within 48-72 hours from the moment of hospitalization.
Results. It was found that patients who developed AKI on the first day had high rates of erythrocyte sedimentation rate (ESR), C-reactive protein, increased troponin, leukocyturia, they more often received inotropic support on the first day of hospitalization.
Conclusion. In patients hospitalized with ADHF, the development of AKI is associated with greater inflammatory activity, greater myocardial damage, and more frequent use of inotropic support in the first day of hospitalization.
About the Authors
S. L. Glizer
Krasnoyarsk State Medical University named after Prof. V.F.Voino-Yasenetsky
Russian Federation
Russian Federation
1, P. Zheleznyaka Str., Krasnoyarsk, 660022
O. A. Shtegman
Krasnoyarsk State Medical University named after Prof. V.F.Voino-Yasenetsky
Russian Federation
Russian Federation
1, P. Zheleznyaka Str., Krasnoyarsk, 660022
M. M. Petrova
Krasnoyarsk State Medical University named after Prof. V.F.Voino-Yasenetsky
Russian Federation
Russian Federation
1, P. Zheleznyaka Str., Krasnoyarsk, 660022
A. V. Shulmin
Vitebsk State Order of Friendship of Peoples Medical University
Belarus
Belarus
References
1. Groenewegen A., Rutten F.H., Mosterd A., Hoes A.W. .Epidemiology of heart failure. Eur J Heart Fail. 2020 Aug. 22(8). 1342-1356. DOI: 10.1002/ejhf.1858
2. Zarudskij A.A., Sheljakina E.V., Shkileva I.J., Peruckaja E.A., Peruckij D.N. Epidemiology of systolic heart failure of systolicheart failure in our days. Health and Education Millennium. 2017.19 (12). 167-171. in Russian. http:// dx.doi.org/10.26787/nydha-2226-7425-2017-19-12-167-171/
3. Polyakov D.S., Fomin I.V., Belenkov Yu.N., Mareev V.Yu., Ageev F.T., Artemyeva E.G., Badin Yu.V., Bakulina E.V., Vinogradova N.G., Galyavich A.S., Ionova T.S., Kamalov G.N., Kechedzhieva S.G., Koziolova N.A., Malenkova V.Yu., Malichkova S.V., Mareev Yu.V., Smirnova E.A., Tarlovskaya E.I., Shcherbina E.V., Yakushin S.S. Chronic heart failure in the Russian Federation: what has changed over 20 years of follow-up? Results of the EPOCH-CHF study. Kardiologiia. 2021. 61(4). 4–14. in Russian.
4. Orso F., Fabbri G., Maggioni P. Epidemiology of heart failure. Handbook of experimental pharmacology. 2017. 243. 15-33.
5. Reznik E.V., Nikitin I.G. Сardiorenal syndrome in patients with chronic heart failure as a stage of the cardiorenal continuum (part I): definition, classification, pathogenesis, diagnosis, epidemiology. The Russian Archives of Internal Medicine. 2019. 9(1). 5-22. in Russian. DOI: 10.20514/2226-6704-2019-9-1-5-22
6. Lee T. H., Fan P. C., Chen J. J., Wu V.C., Lee C.C., Yen C., Kuo G., Hsu H., Tian Y.C., Chang C.H. A validation study comparing existing prediction models of acute kidney injury in patients with acute heart failure. Scientific reports. 2021 May 27. 11(1). 11213. DOI: 10.1038/s41598-021-90756-9
7. Schelkanovtseva E.S., Mironova O.U., Fomin V.V. Biomarkers of acute kidney disease. Potential application in practice. Consilium Medicum. 2021. 23(1). 15-19. in Russian. DOI: 10.26442/20751753.2021.1.200729
8. Kirichenko A.A., Polyakova O.A. C-reactive protein and cardiovascular diseases. Poliklinika. 020. 6. 50–53. In Russian.
9. Ong S.B., Hernández-Reséndiz S., Crespo-Avilan G.E., Mukhametshina R.T., Kwek X.Y., Cabrera-Fuentes H.A., Hausenloy D.J. Inflammation following acute myocardial infarction: Multiple players, dynamic roles, and novel therapeutic opportunities. Pharmacology & therapeutics. 2018. 186. 73-87. DOI:10.1016/j.pharmthera.2018.01.001
10. Sitnikova M.Yu., Lelyavina T.A., Shlyakhto E.V., Dorofeikov V.V. Prognostic value of markers of severity of chronic heart failure. Russian medical journal. 2009. 6. 27-32. In Russian.
11. Chaulin A.M., Duplyakov D.V. Biomarkers of Acute Myocardial Infarction: Diagnostic and Prognostic Value. Part 1. Journal of Clinical Practice. 2020.11(3). 75–84. In Russian. DOI: 10.17816/clinpract34284
12. Koshkina D.E., A.A. Skvortsov, V.N. Protasov, Narusov O.Yu., Tereshchenko S.N. The role of markers of organ damage in patients with chronic heart failure. Cardiology. 2015.55(1). 70–76. in Russian. DOI: 10.18565/cardio.2015.1.70-76
13. Graversen H.V., Norgaard M., Nitsch D., Christiansen C.F. Preadmission kidney function and risk of acute kidney injury in patients hospitalized with acute pyelonephritis: A Danish population-based cohort study. PLoS One. 2021 Mar. 16(3). e0247687. DOI: 10.1371/journal.pone.0247687
14. Barylski M., Nikfar S., Mikhailidis D.P., Toth P.P., Salari P., Ray K.K., Pencina M.J., Rizzo M., Rysz J., Abdollahi M., Nicholls S.J., Banach M. Statins decrease all-cause mortality only in CKD patients not requiring dialysis therapy — a meta-analysis of 11 randomized controlled trials involving 21,295 participants. Pharmacological research. 2013. 72. 35–44. DOI:10.1016/j.phrs.2013.03.007
15. Baigent C., Landray M.J., Reith C., Emberson J., Wheeler D.C., Tomson C., Wanner C., Krane V., Cass A., Craig J., Neal B., Jiang L., Hooi L.S., Levin A., Agodoa L., Gaziano M., Kasiske B., Walker R., Massy Z.A., Feldt-Rasmussen B., Krairittichai U., Ophascharoensuk V., Fellström B., Holdaas H., Tesar V., Wiecek A., Grobbee D., Zeeuw D., Grönhagen-Riska C., Dasgupta T., Lewis D., Herrington W., Mafham M., Majoni W., Wallendszus K., Grimm R., Pedersen T., Tobert J., Armitage J., Baxter A., Bray C., Chen Y., Chen Z., Hill M., Knott C., Parish S., Simpson D., Sleight P., Young A., Collins R. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet. 2011 Jun. 377 (9784). 2181–2192. DOI: 10.1016/S0140-6736(11)60739-3
16. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) / Scandinavian Simvastatin Survival Study Group. Lancet. 1994 Nov. 344.1383–1389.
17. Yasuda H., Yuen P.S., Hu X., Zhou H., Star R.A. Simvastatin improves sepsis-induced mortality and acute kidney injury via renal vascular effects. Kidney international. 2006 May. 69(9). 1535-42.
Review
For citations:
Glizer S.L., Shtegman O.A., Petrova M.M., Shulmin A.V. PREDICTORS OF ACUTE KIDNEY DAMAGE IN PATIENTS HOSPITALIZED WITH ACUTE DECOMPENSATED HEART FAILURE. Transbaikalian Medical Bulletin. 2022;(3):36-43. (In Russ.) https://doi.org/10.52485/19986173_2022_3_36
Views:
77
Email this article 